NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its board has initiated a share repurchase plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 3.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

Alexion Pharmaceuticals (NASDAQ:ALXN) posted its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Zacks' consensus estimate of $1.50 by $0.18. The biopharmaceutical company earned $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. Alexion Pharmaceuticals's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

20 brokerages have issued 12 month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $156.95 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include GlaxoSmithKline (GSK), Bayer (BAYRY), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron Pharmaceuticals (REGN), Astellas Pharma (ALPMY) and Shiseido (SSDOY).

News coverage about ALXN stock has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.20 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 48.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Alexion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.03%), Northern Trust Corp (1.28%), Franklin Resources Inc. (1.00%), BB Biotech AG (0.63%), Wells Fargo & Company MN (0.59%) and Eaton Vance Management (0.52%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Amundi Pioneer Asset Management Inc., State of Tennessee Treasury Department, Franklin Resources Inc., American Century Companies Inc., Federated Investors Inc. PA, Prudential Financial Inc. and Nuveen Asset Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, PointState Capital LP, Redmile Group LLC, Westfield Capital Management Co. LP, FIL Ltd, Braun Stacey Associates Inc., Wells Fargo & Company MN and SG Americas Securities LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $117.74.

Alexion Pharmaceuticals has a market capitalization of $26.20 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.